The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a ...
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.
By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...